Cargando…

Pretreatment and Coadministration With Methotrexate Improved Durability of Pegloticase Response: An Observational, Proof-of-Concept Case Series

Pegloticase is used for treatment of refractory gout, which has failed maximal medical management, but only 42% of patients respond completely to treatment because of the presumed development of antidrug antibodies, which rapidly clear the pegloticase molecule. Immunomodulatory medications temper an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Botson, John K., Peterson, Jeff
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8746906/ https://www.ncbi.nlm.nih.gov/pubmed/33044389 http://dx.doi.org/10.1097/RHU.0000000000001639

Ejemplares similares

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
por: Botson, John K., et al.
Publicado: (2022)

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
por: Botson, John K., et al.
Publicado: (2022)

Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy
por: Dalbeth, Nicola, et al.
Publicado: (2022)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
por: Botson, John K., et al.
Publicado: (2022)

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020)

The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis
por: Liu, Yong, et al.
Publicado: (2014)

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

PEG-ing down (and preventing?) the cause of pegloticase failure
por: Abeles, Aryeh M
Publicado: (2014)

Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept
por: Kaddurah-Daouk, R, et al.
Publicado: (2011)

Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha, Rita N, et al.
Publicado: (2018)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Hemodynamic effect of avanafil and glyceryl trinitrate coadministration
por: Swearingen, Dennis, et al.
Publicado: (2013)

A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of Concept
por: Rahmani, Benyamin, et al.
Publicado: (2019)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)

Coadministration of Liraglutide With Tacrolimus in Kidney Transplant Recipients: A Case Series
por: Pinelli, Nicole R., et al.
Publicado: (2013)

Radiolabeled methotrexate as a diagnostic agent of inflammatory target sites: A proof-of-concept study
por: Papachristou, Maria, et al.
Publicado: (2018)

Pegloticase Induced Hemolytic Anemia in a Patient With G6PD Deficiency
por: Adashek, Michael L., et al.
Publicado: (2018)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study
por: Chen, Sarah K, et al.
Publicado: (2020)

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
por: Lipsky, Peter E, et al.
Publicado: (2014)

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
por: Morton, Allan H., et al.
Publicado: (2018)

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
por: Calabrese, Leonard H., et al.
Publicado: (2017)

BK Viremia Exacerbation With Adalimumab Coadministration
por: Lum, Erik L., et al.
Publicado: (2020)

Personalized Response of Parkinson’s Disease Gut Microbiota to Nootropic Medicinal Herbs In Vitro: A Proof of Concept
por: Peterson, Christine Tara, et al.
Publicado: (2023)

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)

Effect of centchroman coadministration on the pharmacokinetics of metformin in rats
por: Lal, Jawahar, et al.
Publicado: (2010)

Ketamine–Propofol Coadministration for Induction and Infusion Maintenance in Anesthetized Dogs: Effects on Electroencephalography and Antinociception
por: Ko, Jeff C., et al.
Publicado: (2023)

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase
por: Keenan, Robert T., et al.
Publicado: (2019)

The Versatile Transceiver Proof of Concept
por: Troska, J, et al.
Publicado: (2009)

Reduced exposure of imatinib after coadministration with acetaminophen in mice
por: Nassar, Inthisham, et al.
Publicado: (2009)

Teratogenic Effects of Coadministration of Fluoxetine and Olanzapine on Rat Fetuses
por: Bakhtiarian, Azam, et al.
Publicado: (2014)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
por: Alhadab, Ali A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_31u855iqia6vmlmmr6i9s064dg